Abstract: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.
Type:
Grant
Filed:
August 15, 2007
Date of Patent:
May 11, 2010
Assignee:
Roche Palo Alto LLC
Inventors:
Joshua Kennedy-Smith, Wylie Solang Palmer, Zachary Kevin Sweeney
Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
Type:
Grant
Filed:
December 11, 2006
Date of Patent:
May 11, 2010
Assignee:
Roche Palo Alto LLC
Inventors:
Eun Kyung Lee, Chris Richard Melville, David Mark Rotstein
Abstract: Methods and pharmaceutical compositions relating to selective antagonists of the 5-HT6 receptor and 5-HT2A receptor useful for the treatment of cognitive disorders are presented.
Type:
Grant
Filed:
September 30, 2005
Date of Patent:
May 11, 2010
Assignee:
Roche Palo Alto LLC
Inventors:
Douglas William Bonhaus, Renee Sharon Martin
Abstract: A method of associating a phenotype with one or more candidate chromosomal regions in a genome of an organism includes the step of deriving a phenotypic data structure that represents differences in phenotypes between different strains of the organism. Further, a genotypic data structure is established. The genotypic data structure corresponds to a locus selected from a plurality of loci in the genome of the organism. The genotypic data structure represents variations of at least one component of the locus between different strains of the organism. The phenotypic data structure is compared to the genotypic data structure to form a correlation value. The process of establishing a genotypic data structure and comparing it to the phenotypic data structure is repeated for each locus in the plurality of loci, thereby identifying one or more genotypic data structures that form a high correlation value relative to all other compared genotypic data structures.
Type:
Grant
Filed:
December 11, 2001
Date of Patent:
April 13, 2010
Assignee:
Roche Palo Alto LLC
Inventors:
Jonathan A. Usuka, Andrew Grupe, Gary Allen Peltz
Abstract: This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-III: wherein, variables R, X, Y1, Y2, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.
Type:
Grant
Filed:
February 5, 2009
Date of Patent:
March 23, 2010
Assignee:
Roche Palo Alto LLC
Inventors:
Nolan James Dewdney, Joshua Kennedy-Smith, Rama K. Kondru, Bradley E. Loc, Yan Lou, Joel McIntosh, Timothy D. Owens, Michael Soth, Zachary Kevin Sweeney, Joshua Paul Gergely Taygerly
Abstract: The present invention relates to assays that can measure the activity of enzymes that catalyze phosphate modifications, such as kinases, phosphatases, cyclases and phosphodiesterases. The assays can also be used to identify and screen for substances that modulate the activity of kinases, phosphatases, cyclases and phosphodiesterases.
Abstract: Compounds having the formula i wherein m, R1, R2, R4 and X1 are herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates used in the process.
Type:
Grant
Filed:
April 28, 2006
Date of Patent:
March 9, 2010
Assignee:
Roche Palo Alto LLC
Inventors:
James F. Blake, Jay Bradford Fell, John P. Fischer, Robert Than Hendricks, Stacey Renee Spencer, Peter J. Stengel
Abstract: Compounds of the formula I, II or III: or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.
Type:
Grant
Filed:
June 20, 2007
Date of Patent:
March 2, 2010
Assignee:
Roche Palo Alto LLC
Inventors:
Ralph New Harris, III, James M. Kress, David Bruce Repke, Russell Stephen Stabler
Abstract: The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficiency virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficiency virus containing a compound according to formula I where R1, R2, R3, R4, R5, are as defined herein.
Type:
Grant
Filed:
July 27, 2005
Date of Patent:
February 23, 2010
Assignee:
Roche Palo Alto LLC
Inventors:
James Patrick Dunn, Todd Richard Elworthy, Dimitrios Stefanidis, Zachary Kevin Sweeney
Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R1, R2, R3, and R4 are as defined herein.
Inventors:
Allen T. HOPPER, Joan Marie CAROON, Elbert CHIN, Robert F. DUNN, Sharada Shenvi LABADIE, Jim LI, Richard Allen SCHUMACHER, Francisco Xavier TALAMAS
Abstract: Compounds of formula I: wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds, pharmaceutical compositions, methods of using the compounds for treatment of p38 MAP kinase-mediated diseases, and methods of using the compounds for treatment of Raf kinase-mediated diseases.
Type:
Grant
Filed:
November 8, 2007
Date of Patent:
January 12, 2010
Assignee:
Roche Palo Alto LLC
Inventors:
Tobias Gabriel, Joel McIntosh, Kin-Chun Thomas Luk
Abstract: The present invention provides compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
Type:
Grant
Filed:
November 29, 2006
Date of Patent:
December 29, 2009
Assignee:
Roche Palo Alto LLC
Inventors:
Robert Greenhouse, Saul Jaime-Figueroa, Stephen M. Lynch, Lubica Raptova, Karin Ann Stein, Robert James Weikert
Abstract: The present invention provides a novel method for preparing a key intermediate, 3-amino-pentan-1,5-diol (2), which is useful for the preparation of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)-propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidine-7-one (1) a MAP-kinase inhibitor useful in the treatment of rheumatoid arthritis.
Abstract: The invention relates to a novel process for the preparation of 4?-azido-cytidine (I) or a pharmaceutically accepted salt thereof. The compound of formula I is useful for treating virus mediated diseases, particularly for treating HCV mediated diseases.
Type:
Grant
Filed:
December 7, 2007
Date of Patent:
December 15, 2009
Assignee:
Roche Palo Alto LLC
Inventors:
Peter John Harrington, Stefan Hildbrand, Keshab Sarma
Abstract: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPD.
Type:
Grant
Filed:
March 28, 2008
Date of Patent:
December 1, 2009
Assignee:
Roche Palo Alto LLC
Inventors:
David Mark Rotstein, Chris Richard Melville
Abstract: The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R1-R5, R11c and X1 are as defined herein.
Type:
Grant
Filed:
April 22, 2005
Date of Patent:
December 1, 2009
Assignee:
Roche Palo Alto LLC
Inventors:
James Patrick Dunn, Donald Roy Hirschfeld, Tania Silva, Zachary Kevin Sweeney, Harit Vora
Abstract: The present invention provides compounds of formula I where R1 to R4 are as defined herein which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides for methods of treating or preventing HIV infection with compounds according to formula I and compositions containing the same. The invention still further provides process for the preparation of compounds of formula I wherein R4 is A1 and X1 is NH or O.
Type:
Grant
Filed:
September 29, 2006
Date of Patent:
December 1, 2009
Assignee:
Roche Palo Alto LLC
Inventors:
Yoshihito David Saito, Mark Smith, Zachary Kevin Sweeney
Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
Type:
Grant
Filed:
September 18, 2007
Date of Patent:
December 1, 2009
Assignee:
Roche Palo Alto LLC
Inventors:
Remy Lemoine, Chris Richard Melville, David Mark Rotstein, Jutta Wanner
Abstract: Compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ar, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, methods of preparing the compounds, and method of using the compounds for treatment of monoamine reuptake inhibitor-mediated diseases.
Type:
Grant
Filed:
May 31, 2007
Date of Patent:
November 24, 2009
Assignee:
Roche Palo Alto LLC
Inventors:
Ryan Craig Schoenfeld, Robert James Weikert